Expert view: High-throughput analytics for smarter cell-line development
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
Glycosylation is a critical antibody quality attribute linked directly to the efficacy and safety of commercial biologics. While there are various methodologies available for glycan analysis, there is also an increasing need for the development of high-throughput approaches applicable to early stage cell-line development. Octet instruments offer cell-line development scientists a platform for the rapid titer of antibody clones and sialic acid content screening. Combining the sialic acid content data with titer provides in-depth knowledge that can facilitate more informed decisions.